Finance and market news website AusBiz co-founders Kylie Merritt and David Koch interviewed Starpharma CEO Dr Jackie Fairley to discuss DEP® irinotecan moving into Phase 2 and how Starpharma is investigating product concepts for SPL7013 in the fight against COVID-19.

To watch the full interview click here

Starpharma today announced successful completion of the phase 1 component of its phase 1 / 2 trial for DEP^® irinotecan. The trial met its objective of evaluating safety, tolerability, pharmacokinetics and preliminary efficacy data, and identifying a recommended phase 2 dose. The trial will now transition seamlessly into phase 2, with recruitment activities underway at three sites. Two additional sites, The Beatson West of Scotland Cancer Centre (the Beatson) and the Kinghorn Cancer Centre in Sydney are also expected to commence recruitment shortly.

Starpharma has been invited to present today at the Macquarie Australia Conference. Due to COVID-19, the Macquarie Australia Conference will be a virtual conference for registered institutional investors. The event will provide international and domestic institutions with the opportunity to hear from a range of invited Australian companies over three days. Starpharma is one of a handful of companies in the pharmaceutical/biotech and healthcare industries to be presenting during the conference.

US biotech publication BioWorld noted that a number of Australian biotech companies have been testing agents in the fight against COVID-19, in particular highlighting Starpharma’s SPL7013 which showed significant positive antiviral activity against the SARS-CoV-2 virus.

To read the full article, click here

The Australian Financial Review interviewed Starpharma CEO Dr Jackie Fairley for an article highlighting the company’s finding that its antiviral dendrimer SPL7013 showed significant activity against coronavirus. The article noted SPL7013 is already used in existing and approved products within Starpharma’s VivaGel^® portfolio.

To read the full article, click here (paywall).

NASDAQ covered the news that Starpharma’s VivaGel^® active, astodrimer sodium (SPL7013), showed significant antiviral activity against the coronavirus that causes COVID-19. The piece noted the testing was conducted by an external laboratory, 360Biolabs.

To read the full article, click here.

Leading biotech industry portal BioSpace covered Starpharma’s finding that its proprietary dendrimer SPL7013 showed significant activity against  SARS-CoV-2, the coronavirus that causes COVID-19. It noted Starpharma will evaluate product concepts and formulation options for SPL7013 which may have potential applications in the prevention and management of COVID-19.

To read the full article, click here

Starpharma today announced that its proprietary VivaGel^® active, astodrimer sodium (SPL7013), has been shown in laboratory studies to have significant antiviral activity against the coronavirus that causes COVID-19 (coronavirus disease). SPL7013 inhibited the infection of cells with the SARS-CoV-2 virus and the finding was validated by replicate testing against a positive control compound, remdesivir (Gilead), which is considered a leading candidate for the treatment of COVID-19. The finding was also significant given that SPL7013 was reported to be the best performing test compound against SARS-CoV-2 in the laboratory’s assay to date. With these positive results, Starpharma is evaluating product concepts and formulation options for SPL7013, which may have potential applications in the prevention and management of COVID-19.

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2020.

Starpharma’s cash balance as at 31 March 2020 was $36.1 million, an increase of $0.2 million compared to the previous quarter’s cash balance. Net operating cash outflows for the quarter were $0.9 million, or $6.0 million for the nine months to 31 March 2020. Starpharma’s strong cash reserves and clean balance sheet places the Company in a strong position to continue to progress its commercial and R&D activities in the current uncertain global environment of the COVID-19 pandemic.

Starpharma continues to closely monitor the COVID-19 pandemic and its impact.